UK markets closed
  • NIKKEI 225

    -57.75 (-0.21%)

    +231.73 (+0.88%)

    -0.06 (-0.09%)

    +0.20 (+0.01%)
  • DOW

    -323.73 (-0.92%)

    +996.60 (+3.59%)
  • CMC Crypto 200

    +50.30 (+5.43%)
  • ^IXIC

    +19.24 (+0.13%)
  • ^FTAS

    +10.68 (+0.26%)

Regenerative Medicine Market - Global Outlook and Forecast 2021-2026 - Increasing Demand For Car T-Cell Therapies -

·5-min read

DUBLIN, Jun 15, 2021--(BUSINESS WIRE)--The "Regenerative Medicine Market - Global Outlook and Forecast 2021-2026" report has been added to's offering.

The regenerative medicine market size to grow at a CAGR of around 34% during the period 2020-2026.

Increased R&D investments by pharmaceutical companies will drive the demand for regenerative medicines. Europe plays a significant role in supporting the development and authorization of these products for several genetic and rare disorders. Increased funding via several venture capitalists and governments, and private institutions contribute significantly to the global regenerative medicine market growth.

The increased prevalence of diseases such as cardiovascular diseases and diabetes can drive cell and gene therapy and tissue-engineered products. With the rise in thermal burns, occupational burn accidents, and chronic wounds, regenerative medicine products will experience steady growth. Novartis and Gilead Sciences are the key companies offering various therapies to treat cancer, genetic, and rare disorders.

The report considers the present scenario of the regenerative medicine market and its market dynamics for 2019-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.


The regenerative medicine market research report includes a detailed segmentation by application, products, end-users, geography. Oncology constitutes the largest portion of the global regenerative medicine market share. The development of curative therapies by CAR-T and cell and gene therapies is widely popularized in the oncology therapeutic area. The increasing global prevalence rates and the increasing rates of different types of life-threatening cancers are the most important key factors that drive the oncology segment.

Consistent innovations in gene therapies due to the increased number of clinical trials and pipeline products are driving the growth prospects. Hence, the increased inflow of funding for the development of gene therapy is one of the driving factors for the sector growth. Cell therapy is the major revenue contributor. The increasing prevalence of diabetes and foot ulcers is the primary factor contributing to the growth of tissue-engineered products. The tissue-engineered product segment to grow at a CAGR of 8% by 2026.

Hospitals are likely to remain a dominant revenue contributor to the global regenerative medicine market. Around 50% of therapeutic surgeries performed in the US annually, including cardiovascular and musculoskeletal, occur in hospitals. Cancer care centers are likely to witness an incremental growth of approx. USD 10 billion by 2026.

As cancer is the second leading cause of death across the globe, which is responsible for approx. 10 million deaths annually, the scope of cancer centers is growing. Key vendors are focusing more on cancer care centers than hospitals to promote their products. As the cancer centers are being covered under reimbursement schemes, the growth of these facilities is likely to increase during the forecast period.


1. How big is the regenerative medicine market?

2. What are the critical applications of regenerative medicine products?

3. Who are the key players in the regenerative medicine market?

4. Which segment accounted for the largest regenerative medicine market share?

5. Which region holds the largest share in the global regenerative medicine market?

6. How has the COVID-19 pandemic affected the regenerative medicine industry?

Key Vendors

  • Novartis

  • Gilead Sciences

  • Amgen

  • Organogenesis

  • Bristol Myers Squibb

  • Vericle

  • Osiris Therapeutics

Other Prominent Vendors

  • Anges

  • Orchard Therapeutics

  • Orthofix

  • Integra Life Science

  • MiMedx

  • bluebird bio

  • Mesoblast

  • Avita Medical

  • Takeda Pharmaceuticals

  • Medipost

  • TissueTech

  • Misonix

  • J-TEC

  • Stempeutics

  • CO.DON

  • GC Pharma

  • Orthocell

  • Tego Science

  • Nipro


  • APAC Biotech

  • Bio Solution

  • Chiesi Farmaceutici

  • Collplant

  • Corestem

  • Human Stem Cell Institute

  • JCR Pharmaceuticals

  • JW CreaGene

  • Nuvasive

  • Sibiono GeneTech

  • Shanghai Sunway Biotech

  • Terumo

Key Topics Covered:

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage

5 Report Assumptions & Caveats

6 Market at a Glance

7 Introduction

8 Market Opportunities & Trends

8.1 Latest Advances In Tissue-Engineering Therapies

8.2 Robust Product Pipeline Of Regenerative Medicine Companies

8.3 Strategic Acquisitions By Regenerative Medicine Companies

9 Market Growth Enablers

9.1 Increase In Acute, Chronic, & Genetic Disorders

9.2 Increasing Demand For Car T-Cell Therapies

9.3 Faster Regulatory Approvals & Special Designations Of Rm Products

10 Market Restraints

10.1 Manufacturing, Operational, & Ethical Challenges

10.2 High Cost of Regenerative Therapies

10.3 Outbreak of The COVID-19 Pandemic

11 Market Landscape

11.1 Market Overview

11.2 Market Size & Forecast

11.3 Five Forces Analysis

12 Application

12.1 Market Snapshot & Growth Engine

12.2 Market Overview

12.3 Dermatology

12.4 Musculoskeletal

12.5 Oncology

12.6 Genetic Disorders

13 Product

13.1 Market Snapshot & Growth Engine

13.2 Market Overview

13.3 Gene Therapy

13.4 Cell Therapy

13.5 Tissue-Engineering

14 End-Users

14.1 Market Snapshot & Growth Engine

14.2 Market Overview

14.3 Hospitals

14.4 Cancer Care Centers

14.5 Wound Care Centers

14.6 Ambulatory Surgical Centers

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting